Hematology

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.

The study findings suggest that, while the link between chronic lymphocytic leukemia and melanoma had been known, the rate at which the link occurs is higher than expected.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial.

Top news of the day from across the health care landscape.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

Selinexor (Xpovio, Karyopharm) received approval in combination with dexamethasone for heavily-pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (vWD) have been among the most common conditions addressed in these practice locations.

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

In a Specialty Pharmacy Times® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.

Treatment with tagraxofusp yielded high response rates in patients with blastic plasmacytoid dendritic cell neoplasm.

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (VWD) have been among the most common conditions addressed at these practice locations.